Yining Huang is a research scientist at Eli Lilly and company. At Lilly, he supports drug development for pre-clinical and clinical stage assets, including monoclonal antibodies and therapeutic proteins using mass spectrometry-based protein characterization techniques. Dr. Huang is also leading collaborations between Lilly and academic institutions on the topic of protein higher-order structure analysis by MS. Dr. Huang received his B.S. in Chemistry from Peking University and earned his Ph.D. in Chemistry from Washington University in St. Louis. In his graduate research with Dr. Michael L. Gross, he focused on implementing MS-based methods, including: hydrogen-deuterium exchange, fast photochemical oxidation of proteins, native MS, as well as ion mobility for studying protein-protein interactions in malaria and viral infectious diseases. Dr. Huang was a recipient of the McDonell Scholarship at Washington University. In his academic and research career, he authored and co-authored multiple publications in protein structural studies, which are crucial for vaccine and therapy development.